{"DataElement":{"publicId":"3305426","version":"1","preferredName":"Concomitant Medication Hormone Replacement Therapy Therapeutic Procedure Relationship Adverse Event Administered Name","preferredDefinition":"the name of the concomitant hormone replacement agent, treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production, administered for the treatment of an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure.","longName":"3305253v1.0:3305285v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3305253","version":"1","preferredName":"Concomitant Medication Hormone Replacement Therapy Therapeutic Procedure Relationship Adverse Event Administered","preferredDefinition":"information related to the administration of a concomitant hormone replacement therapy, treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production, for the treatment of an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure.","longName":"2206481v1.0:3305251v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206481","version":"1","preferredName":"Concomitant Medication","preferredDefinition":"Concomitant; following as a consequence.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C25730:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F6E6-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3305251","version":"1","preferredName":"Hormone Replacement Therapy Therapeutic Procedure Relationship Adverse Event Administered","preferredDefinition":"Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Related; connected or associated.:Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:The act of having given something (e.g., a medication or test).","longName":"3305251v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Replacement Therapy","conceptCode":"C15599","definition":"Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0C96-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0CA7-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3305285","version":"1","preferredName":"Hormone Replacement Therapy Name","preferredDefinition":"The name of Hormone Replacement Therapy agent.","longName":"3305285v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Thyroid USP","valueDescription":"Thyroid USP","ValueMeaning":{"publicId":"3305286","version":"1","preferredName":"Thyroid USP","longName":"3305286","preferredDefinition":"a natural preparation combining levothyroxine (T 4 ) and liothyronine (T 3 ) for use as a thyroid hormone replacement to treat hypothyroidism","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-70AE-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-70C7-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Hydrocortisone","valueDescription":"Therapeutic Hydrocortisone","ValueMeaning":{"publicId":"3305287","version":"1","preferredName":"Therapeutic Hydrocortisone","longName":"3305287","preferredDefinition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Hydrocortisone","conceptCode":"C555","definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-70D1-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-70EA-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Levothyroxine","valueDescription":"Levothyroxine","ValueMeaning":{"publicId":"3305288","version":"1","preferredName":"Levothyroxine","longName":"3305288v1.00","preferredDefinition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levothyroxine","conceptCode":"C62080","definition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-70F6-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"GDEEN","dateModified":"2023-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-710F-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Liothyronine","valueDescription":"Liothyronine","ValueMeaning":{"publicId":"3305290","version":"1","preferredName":"Liothyronine","longName":"3305290","preferredDefinition":"A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liothyronine","conceptCode":"C907","definition":"A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-711C-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-7135-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Liotrix","valueDescription":"Liotrix","ValueMeaning":{"publicId":"3305292","version":"1","preferredName":"Liotrix","longName":"3305292","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liotrix","conceptCode":"C87251","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7142-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-715B-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1F1F71A-7165-08C4-E040-BB89AD43052C","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ONEDATA","dateModified":"2011-11-17","deletedIndicator":"No"},{"value":"Testosterone","valueDescription":"Testosterone","ValueMeaning":{"publicId":"2579543","version":"1","preferredName":"Testosterone","longName":"2579543","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-03C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-06-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C2B80E-EFA9-E642-E050-BB89AD4323F1","beginDate":"2014-11-13","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435033","version":"1","preferredName":"Techniques","preferredDefinition":"A practiced and regimented skill or series of actions.","longName":"C16847","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87DA-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7099-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ROUILLAS","dateModified":"2014-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Hormonal Replacement Therapy","type":"Preferred Question Text","description":"Hormonal Replacement Therapy Name","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Hormonal Replacement Therapy Agent Name","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-71B1-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"ROUILLAS","dateModified":"2014-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}